Tatsis Ourania 4

What Happened

• Ourania Tatsis, EVP and Chief Regulatory & Quality Officer at Vertex Pharmaceuticals (VRTX), sold 1,500 shares in an open-market sale on 2026-07-02 at $524.99 per share, generating $787,485 in proceeds. Sales are often routine and do not necessarily indicate a change in sentiment.

Key Details

• Transaction date and price: 2026-07-02 — 1,500 shares at $524.99 each.
• Total value: $787,485.
• Transaction type: Sale (open-market/private sale reported as "S").
• Shares owned after transaction: Not disclosed in this filing.
• Footnote: Sale was made pursuant to a company-approved Rule 10b5-1 trading plan entered into on 08/21/2025.
• Filing timeliness: Form filed 2026-07-07 for a 2026-07-02 trade — this appears to exceed the standard two-business-day Form 4 reporting window.

Context

• The sale was executed under a pre-established 10b5-1 plan, which allows insiders to trade according to a preset program and is often used to avoid questions about trading on material nonpublic information. As a sale (not a purchase), it is generally considered less informative about the insider's forward-looking view of the company.